Russell Investments Group, Ltd. Chemo Centryx, Inc. Transaction History

Russell Investments Group, Ltd.

$66.8 Billion
Q3 2024

Shares

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2021 Nov 08, 2021	SELL	$13.18 - $19.83 $38,195 - $57,467	-2,898 Closed	0 $0
Q2 2021 Aug 04, 2021	SELL	$9.59 - $50.88 $237,045 - $1.26 Million	-24,718 Reduced 89.51%	2,898 $38,000
Q1 2021 May 10, 2021	BUY	$49.53 - $68.4 $8,271 - $11,422	167 Added 0.61%	27,616 $1.41 Million
Q4 2020 Feb 08, 2021	SELL	$47.25 - $65.16 $29,956 - $41,311	-634 Reduced 2.26%	27,449 $1.7 Million
Q3 2020 Nov 09, 2020	SELL	$46.35 - $61.69 $7,045 - $9,376	-152 Reduced 0.54%	28,083 $1.54 Million
Q2 2020 Aug 05, 2020	BUY	$38.58 - $65.07 $569,479 - $960,498	14,761 Added 109.55%	28,235 $1.62 Million
Q1 2020 May 06, 2020	BUY	$32.73 - $50.78 $441,004 - $684,209	13,474 New	13,474 $540,000
Q3 2019 Nov 01, 2019	SELL	$6.47 - $8.96 $304,795 - $422,096	-47,109 Closed	0 $0
Q2 2019 Aug 09, 2019	SELL	$8.31 - $14.85 $291,199 - $520,373	-35,042 Reduced 42.66%	47,109 $421,000
Q1 2019 May 13, 2019	BUY	$10.01 - $13.89 $147,147 - $204,183	14,700 Added 21.79%	82,151 $1.1 Million
Q4 2018 Feb 11, 2019	BUY	$9.15 - $12.26 $50,114 - $67,148	5,477 Added 8.84%	67,451 $738,000
Q2 2018 Aug 08, 2018	SELL	$10.62 - $13.98 $32,890 - $43,296	-3,097 Reduced 4.76%	61,974 $866,000
Q1 2018 May 11, 2018	BUY	$5.9 - $14.99 $140,095 - $355,937	23,745 Added 57.46%	65,071 $885,000
Q4 2017 Feb 06, 2018	SELL	$5.53 - $8.42 $202,099 - $307,717	-36,546 Reduced 46.93%	41,326 $244,000
Q3 2017 Nov 07, 2017	BUY	$6.5 - $10.69 $506,168 - $832,451	77,872	77,872 $578,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.